Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 633

1.

Clostridium difficile Infection-Daily Symptoms (CDI-DaySyms™) questionnaire: psychometric characteristics and responder thresholds.

Talbot GH, Kleinman L, Davies E, Hunsche E, Revicki D, Roberts L, Rosenberg D, Nord CE.

Health Qual Life Outcomes. 2019 May 3;17(1):77. doi: 10.1186/s12955-019-1142-9.

2.

Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials.

Gerding DN, Cornely OA, Grill S, Kracker H, Marrast AC, Nord CE, Talbot GH, Buitrago M, Gheorghe Diaconescu I, Murta de Oliveira C, Preotescu L, Pullman J, Louie TJ, Wilcox MH.

Lancet Infect Dis. 2019 Mar;19(3):265-274. doi: 10.1016/S1473-3099(18)30614-5. Epub 2019 Jan 29.

3.

The CDI-DaySyms: Content Development of a New Patient-Reported Outcome Questionnaire for Symptoms of Clostridium difficile Infection.

Kleinman L, Talbot GH, Hunsche E, Schüler R, Nord CE.

Value Health. 2018 Apr;21(4):441-448. doi: 10.1016/j.jval.2017.08.3017. Epub 2017 Nov 7. Review.

4.

Erratum to: Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA).

Sartelli M, Weber DG, Ruppé E, Bassetti M, Wright BJ, Ansaloni L, Catena F, Coccolini F, Abu-Zidan FM, Coimbra R, Moore EE, Moore FA, Maier RV, De Waele JJ, Kirkpatrick AW, Griffiths EA, Eckmann C, Brink AJ, Mazuski JE, May AK, Sawyer RG, Mertz D, Montravers P, Kumar A, Roberts JA, Vincent JL, Watkins RR, Lowman W, Spellberg B, Abbott IJ, Adesunkanmi AK, Al-Dahir S, Al-Hasan MN, Agresta F, Althani AA, Ansari S, Ansumana R, Augustin G, Bala M, Balogh ZJ, Baraket O, Bhangu A, Beltrán MA, Bernhard M, Biffl WL, Boermeester MA, Brecher SM, Cherry-Bukowiec JR, Buyne OR, Cainzos MA, Cairns KA, Camacho-Ortiz A, Chandy SJ, Che Jusoh A, Chichom-Mefire A, Colijn C, Corcione F, Cui Y, Curcio D, Delibegovic S, Demetrashvili Z, De Simone B, Dhingra S, Diaz JJ, Di Carlo I, Dillip A, Di Saverio S, Doyle MP, Dorj G, Dogjani A, Dupont H, Eachempati SR, Enani MA, Egiev VN, Elmangory MM, Ferrada P, Fitchett JR, Fraga GP, Guessennd N, Giamarellou H, Ghnnam W, Gkiokas G, Goldberg SR, Gomes CA, Gomi H, Guzmán-Blanco M, Haque M, Hansen S, Hecker A, Heizmann WR, Herzog T, Hodonou AM, Hong SK, Kafka-Ritsch R, Kaplan LJ, Kapoor G, Karamarkovic A, Kees MG, Kenig J, Kiguba R, Kim PK, Kluger Y, Khokha V, Koike K, Kok KY, Kong V, Knox MC, Inaba K, Isik A, Iskandar K, Ivatury RR, Labbate M, Labricciosa FM, Laterre PF, Latifi R, Lee JG, Lee YR, Leone M, Leppaniemi A, Li Y, Liang SY, Loho T, Maegele M, Malama S, Marei HE, Martin-Loeches I, Marwah S, Massele A, McFarlane M, Melo RB, Negoi I, Nicolau DP, Nord CE, Ofori-Asenso R, Omari AH, Ordonez CA, Ouadii M, Pereira Júnior GA, Piazza D, Pupelis G, Rawson TM, Rems M, Rizoli S, Rocha C, Sakakushev B, Sanchez-Garcia M, Sato N, Segovia Lohse HA, Sganga G, Siribumrungwong B, Shelat VG, Soreide K, Soto R, Talving P, Tilsed JV, Timsit JF, Trueba G, Trung NT, Ulrych J, van Goor H, Vereczkei A, Vohra RS, Wani I, Uhl W, Xiao Y, Yuan KC, Zachariah SK, Zahar JR, Zakrison TL, Corcione A, Melotti RM, Viscoli C, Viale P.

World J Emerg Surg. 2017 Aug 2;12:35. doi: 10.1186/s13017-017-0147-0. eCollection 2017.

5.

In-vitro activity of solithromycin against anaerobic bacteria from the normal intestinal microbiota.

Weintraub A, Rashid MU, Nord CE.

Anaerobe. 2016 Dec;42:119-122. doi: 10.1016/j.anaerobe.2016.10.002. Epub 2016 Oct 7.

PMID:
27725229
6.

Role of cephalosporins in the era of Clostridium difficile infection.

Wilcox MH, Chalmers JD, Nord CE, Freeman J, Bouza E.

J Antimicrob Chemother. 2017 Jan;72(1):1-18. Epub 2016 Sep 22. Review.

7.

Methicillin-resistant Staphylococcus aureus in Stockholm, Sweden: Molecular epidemiology and antimicrobial susceptibilities to ceftaroline, linezolid, mupirocin and vancomycin in 2014.

Fang H, Fröding I, Gian B, Hæggman S, Tollström UB, Ullberg M, Nord CE.

J Glob Antimicrob Resist. 2016 Jun;5:31-5. doi: 10.1016/j.jgar.2016.01.012. Epub 2016 Mar 11.

PMID:
27436463
8.

Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA).

Sartelli M, Weber DG, Ruppé E, Bassetti M, Wright BJ, Ansaloni L, Catena F, Coccolini F, Abu-Zidan FM, Coimbra R, Moore EE, Moore FA, Maier RV, De Waele JJ, Kirkpatrick AW, Griffiths EA, Eckmann C, Brink AJ, Mazuski JE, May AK, Sawyer RG, Mertz D, Montravers P, Kumar A, Roberts JA, Vincent JL, Watkins RR, Lowman W, Spellberg B, Abbott IJ, Adesunkanmi AK, Al-Dahir S, Al-Hasan MN, Agresta F, Althani AA, Ansari S, Ansumana R, Augustin G, Bala M, Balogh ZJ, Baraket O, Bhangu A, Beltrán MA, Bernhard M, Biffl WL, Boermeester MA, Brecher SM, Cherry-Bukowiec JR, Buyne OR, Cainzos MA, Cairns KA, Camacho-Ortiz A, Chandy SJ, Che Jusoh A, Chichom-Mefire A, Colijn C, Corcione F, Cui Y, Curcio D, Delibegovic S, Demetrashvili Z, De Simone B, Dhingra S, Diaz JJ, Di Carlo I, Dillip A, Di Saverio S, Doyle MP, Dorj G, Dogjani A, Dupont H, Eachempati SR, Enani MA, Egiev VN, Elmangory MM, Ferrada P, Fitchett JR, Fraga GP, Guessennd N, Giamarellou H, Ghnnam W, Gkiokas G, Goldberg SR, Gomes CA, Gomi H, Guzmán-Blanco M, Haque M, Hansen S, Hecker A, Heizmann WR, Herzog T, Hodonou AM, Hong SK, Kafka-Ritsch R, Kaplan LJ, Kapoor G, Karamarkovic A, Kees MG, Kenig J, Kiguba R, Kim PK, Kluger Y, Khokha V, Koike K, Kok KY, Kong V, Knox MC, Inaba K, Isik A, Iskandar K, Ivatury RR, Labbate M, Labricciosa FM, Laterre PF, Latifi R, Lee JG, Lee YR, Leone M, Leppaniemi A, Li Y, Liang SY, Loho T, Maegele M, Malama S, Marei HE, Martin-Loeches I, Marwah S, Massele A, McFarlane M, Melo RB, Negoi I, Nicolau DP, Nord CE, Ofori-Asenso R, Omari AH, Ordonez CA, Ouadii M, Pereira Júnior GA, Piazza D, Pupelis G, Rawson TM, Rems M, Rizoli S, Rocha C, Sakakushev B, Sanchez-Garcia M, Sato N, Segovia Lohse HA, Sganga G, Siribumrungwong B, Shelat VG, Soreide K, Soto R, Talving P, Tilsed JV, Timsit JF, Trueba G, Trung NT, Ulrych J, van Goor H, Vereczkei A, Vohra RS, Wani I, Uhl W, Xiao Y, Yuan KC, Zachariah SK, Zahar JR, Zakrison TL, Corcione A, Melotti RM, Viscoli C, Viale P.

World J Emerg Surg. 2016 Jul 15;11:33. doi: 10.1186/s13017-016-0089-y. eCollection 2016. Review. Erratum in: World J Emerg Surg. 2017 Aug 2;12 :35.

9.

Ecological Effect of Solithromycin on Normal Human Oropharyngeal and Intestinal Microbiota.

Rashid MU, Rosenborg S, Panagiotidis G, Holm J, Söderberg Löfdal K, Weintraub A, Nord CE.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):4244-51. doi: 10.1128/AAC.00461-16. Print 2016 Jul.

10.

Clostridium difficile recurrences in Stockholm.

Sandell S, Rashid MU, Jorup-Rönström C, Ellström K, Nord CE, Weintraub A.

Anaerobe. 2016 Apr;38:97-102. doi: 10.1016/j.anaerobe.2016.01.005. Epub 2016 Jan 21.

PMID:
26802875
11.

Molecular characteristics of Clostridium difficile strains from patients with a first recurrence more than 8 weeks after the primary infection.

Chen Y, Rashid MU, Huang H, Fang H, Nord CE, Wang M, Weintraub A.

J Microbiol Immunol Infect. 2017 Aug;50(4):532-536. doi: 10.1016/j.jmii.2015.10.017. Epub 2015 Dec 1.

12.

Same Exposure but Two Radically Different Responses to Antibiotics: Resilience of the Salivary Microbiome versus Long-Term Microbial Shifts in Feces.

Zaura E, Brandt BW, Teixeira de Mattos MJ, Buijs MJ, Caspers MP, Rashid MU, Weintraub A, Nord CE, Savell A, Hu Y, Coates AR, Hubank M, Spratt DA, Wilson M, Keijser BJ, Crielaard W.

MBio. 2015 Nov 10;6(6):e01693-15. doi: 10.1128/mBio.01693-15.

13.

Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection.

Gerding DN, Hecht DW, Louie T, Nord CE, Talbot GH, Cornely OA, Buitrago M, Best E, Sambol S, Osmolski JR, Kracker H, Locher HH, Charef P, Wilcox M.

J Antimicrob Chemother. 2016 Jan;71(1):213-9. doi: 10.1093/jac/dkv300. Epub 2015 Oct 3.

14.

WSES guidelines for management of Clostridium difficile infection in surgical patients.

Sartelli M, Malangoni MA, Abu-Zidan FM, Griffiths EA, Di Bella S, McFarland LV, Eltringham I, Shelat VG, Velmahos GC, Kelly CP, Khanna S, Abdelsattar ZM, Alrahmani L, Ansaloni L, Augustin G, Bala M, Barbut F, Ben-Ishay O, Bhangu A, Biffl WL, Brecher SM, Camacho-Ortiz A, Caínzos MA, Canterbury LA, Catena F, Chan S, Cherry-Bukowiec JR, Clanton J, Coccolini F, Cocuz ME, Coimbra R, Cook CH, Cui Y, Czepiel J, Das K, Demetrashvili Z, Di Carlo I, Di Saverio S, Dumitru IM, Eckert C, Eckmann C, Eiland EH, Enani MA, Faro M, Ferrada P, Forrester JD, Fraga GP, Frossard JL, Galeiras R, Ghnnam W, Gomes CA, Gorrepati V, Ahmed MH, Herzog T, Humphrey F, Kim JI, Isik A, Ivatury R, Lee YY, Juang P, Furuya-Kanamori L, Karamarkovic A, Kim PK, Kluger Y, Ko WC, LaBarbera FD, Lee JG, Leppaniemi A, Lohsiriwat V, Marwah S, Mazuski JE, Metan G, Moore EE, Moore FA, Nord CE, Ordoñez CA, Júnior GA, Petrosillo N, Portela F, Puri BK, Ray A, Raza M, Rems M, Sakakushev BE, Sganga G, Spigaglia P, Stewart DB, Tattevin P, Timsit JF, To KB, Tranà C, Uhl W, Urbánek L, van Goor H, Vassallo A, Zahar JR, Caproli E, Viale P.

World J Emerg Surg. 2015 Aug 20;10:38. doi: 10.1186/s13017-015-0033-6. eCollection 2015. Review.

15.

Multicenter, Double-Blind, Randomized, Phase 2 Study Evaluating the Novel Antibiotic Cadazolid in Patients with Clostridium difficile Infection.

Louie T, Nord CE, Talbot GH, Wilcox M, Gerding DN, Buitrago M, Kracker H, Charef P, Cornely OA.

Antimicrob Agents Chemother. 2015 Oct;59(10):6266-73. doi: 10.1128/AAC.00504-15. Epub 2015 Jul 27.

16.

Analysis of effects of MCB3681, the antibacterially active substance of prodrug MCB3837, on human resident microflora as proof of principle.

Dalhoff A, Rashid MU, Kapsner T, Panagiotidis G, Weintraub A, Nord CE.

Clin Microbiol Infect. 2015 Aug;21(8):767.e1-4. doi: 10.1016/j.cmi.2015.05.025. Epub 2015 Jun 3.

17.

Corrigendum to: "Bacteroides fragilis RecA protein overexpression causes resistance to metronidazole." [Res. Microbiol. 161 (5) (2010) 346-354].

Steffens LS, Nicholson S, Paul LV, Nord CE, Patrick S, Abratt VR.

Res Microbiol. 2015 Jun;166(5):e1. doi: 10.1016/j.resmic.2010.07.001. Epub 2010 Jul 30. No abstract available.

18.

Ecological Effect of Ceftaroline-Avibactam on the Normal Human Intestinal Microbiota.

Rashid MU, Rosenborg S, Panagiotidis G, Söderberg-Löfdal K, Weintraub A, Nord CE.

Antimicrob Agents Chemother. 2015 Aug;59(8):4504-9. doi: 10.1128/AAC.00530-15. Epub 2015 May 18.

19.

Impact of Ciprofloxacin and Clindamycin Administration on Gram-Negative Bacteria Isolated from Healthy Volunteers and Characterization of the Resistance Genes They Harbor.

Card RM, Mafura M, Hunt T, Kirchner M, Weile J, Rashid MU, Weintraub A, Nord CE, Anjum MF.

Antimicrob Agents Chemother. 2015 Aug;59(8):4410-6. doi: 10.1128/AAC.00068-15. Epub 2015 May 18.

20.

Ecological effect of ceftazidime/avibactam on the normal human intestinal microbiota.

Rashid MU, Rosenborg S, Panagiotidis G, Löfdal KS, Weintraub A, Nord CE.

Int J Antimicrob Agents. 2015 Jul;46(1):60-5. doi: 10.1016/j.ijantimicag.2015.02.027. Epub 2015 Apr 20.

PMID:
25979639
21.

Determining the Long-term Effect of Antibiotic Administration on the Human Normal Intestinal Microbiota Using Culture and Pyrosequencing Methods.

Rashid MU, Zaura E, Buijs MJ, Keijser BJ, Crielaard W, Nord CE, Weintraub A.

Clin Infect Dis. 2015 May 15;60 Suppl 2:S77-84. doi: 10.1093/cid/civ137.

PMID:
25922405
22.

Development of antimicrobial resistance in the normal anaerobic microbiota during one year after administration of clindamycin or ciprofloxacin.

Rashid MU, Weintraub A, Nord CE.

Anaerobe. 2015 Feb;31:72-7. doi: 10.1016/j.anaerobe.2014.10.004. Epub 2014 Oct 15.

PMID:
25445201
23.

Cdad-Daysyms™: A New Patient-Reported Outcome Tool For Clostridium Difficile-Associated Diarrhoea.

Kleinman L, Talbot GH, Schüler R, Broderick K, Revicki D, Nord CE.

Value Health. 2014 Nov;17(7):A569. doi: 10.1016/j.jval.2014.08.1897. Epub 2014 Oct 26. No abstract available.

24.

Risk factors of Clostridium difficile infections among patients in a university hospital in Shanghai, China.

Huang H, Wu S, Chen R, Xu S, Fang H, Weintraub A, Nord CE.

Anaerobe. 2014 Dec;30:65-9. doi: 10.1016/j.anaerobe.2014.08.015. Epub 2014 Sep 8.

PMID:
25219941
25.

In vitro activity of MCB3681 against Clostridium difficile strains.

Rashid MU, Dalhoff A, Weintraub A, Nord CE.

Anaerobe. 2014 Aug;28:216-9. doi: 10.1016/j.anaerobe.2014.07.001. Epub 2014 Jul 10.

PMID:
25016084
26.

Ecological impact of MCB3837 on the normal human microbiota.

Rashid MU, Dalhoff A, Bäckström T, Björkhem-Bergman L, Panagiotidis G, Weintraub A, Nord CE.

Int J Antimicrob Agents. 2014 Aug;44(2):125-30. doi: 10.1016/j.ijantimicag.2014.03.016. Epub 2014 May 23.

PMID:
24931053
27.

Alternative strategies for proof-of-principle studies of antibacterial agents.

Dalhoff A, Weintraub A, Nord CE.

Antimicrob Agents Chemother. 2014 Aug;58(8):4257-63. doi: 10.1128/AAC.02473-14. Epub 2014 May 27. Review.

28.

Toxin-producing Clostridium difficile strains as long-term gut colonizers in healthy infants.

Adlerberth I, Huang H, Lindberg E, Åberg N, Hesselmar B, Saalman R, Nord CE, Wold AE, Weintraub A.

J Clin Microbiol. 2014 Jan;52(1):173-9. doi: 10.1128/JCM.01701-13. Epub 2013 Oct 30.

29.

What is hot in the anaerobe literature? Clostridium difficile infections.

Nord CE.

Anaerobe. 2013 Dec;24:107-8. doi: 10.1016/j.anaerobe.2013.04.004. Epub 2013 Apr 12. Review. No abstract available.

PMID:
23587754
30.

In vitro activity of cadazolid against Clostridium difficile strains isolated from primary and recurrent infections in Stockholm, Sweden.

Rashid MU, Lozano HM, Weintraub A, Nord CE.

Anaerobe. 2013 Apr;20:32-5. doi: 10.1016/j.anaerobe.2013.02.003. Epub 2013 Feb 26.

PMID:
23454525
31.

Ecological impact of doxycycline at low dose on normal oropharyngeal and intestinal microflora.

Rashid MU, Panagiotidis G, Bäckström T, Weintraub A, Nord CE.

Int J Antimicrob Agents. 2013 Apr;41(4):352-7. doi: 10.1016/j.ijantimicag.2012.11.014. Epub 2013 Jan 16.

PMID:
23332619
32.

An expanded multilocus sequence typing scheme for propionibacterium acnes: investigation of 'pathogenic', 'commensal' and antibiotic resistant strains.

McDowell A, Barnard E, Nagy I, Gao A, Tomida S, Li H, Eady A, Cove J, Nord CE, Patrick S.

PLoS One. 2012;7(7):e41480. doi: 10.1371/journal.pone.0041480. Epub 2012 Jul 30.

33.

Antibiotic resistance patterns of Escherichia coli isolates from different aquatic environmental sources in León, Nicaragua.

Amaya E, Reyes D, Paniagua M, Calderón S, Rashid MU, Colque P, Kühn I, Möllby R, Weintraub A, Nord CE.

Clin Microbiol Infect. 2012 Sep;18(9):E347-54. doi: 10.1111/j.1469-0691.2012.03930.x. Epub 2012 Jun 28.

34.

Effect of new antimicrobial agents on the ecological balance of human microflora.

Rashid MU, Weintraub A, Nord CE.

Anaerobe. 2012 Apr;18(2):249-53. doi: 10.1016/j.anaerobe.2011.11.005. Epub 2011 Dec 2. Review.

PMID:
22155131
35.

Cellulose and PapG are important for Escherichia coli causing recurrent urinary tract infection in women.

Norinder BS, Lüthje P, Yadav M, Kadas L, Fang H, Nord CE, Brauner A.

Infection. 2011 Dec;39(6):571-4. doi: 10.1007/s15010-011-0199-0. Epub 2011 Oct 15.

PMID:
22002732
36.

Effect of telavancin on human intestinal microflora.

Rashid MU, Weintraub A, Nord CE.

Int J Antimicrob Agents. 2011 Dec;38(6):474-9. doi: 10.1016/j.ijantimicag.2011.08.012. Epub 2011 Oct 6.

PMID:
21982049
37.
38.

The role of Bacteroides fragilis RecQ DNA helicases in cell survival after metronidazole exposure.

Paul L, Patrick S, Nord CE, Abratt V.

FEMS Microbiol Lett. 2011 Jun;319(2):125-32. doi: 10.1111/j.1574-6968.2011.02271.x. Epub 2011 Apr 18.

39.

Antibiotic resistance patterns of intestinal Escherichia coli isolates from Nicaraguan children.

Amaya E, Reyes D, Vilchez S, Paniagua M, Möllby R, Nord CE, Weintraub A.

J Med Microbiol. 2011 Feb;60(Pt 2):216-22. doi: 10.1099/jmm.0.020842-0. Epub 2010 Oct 21.

PMID:
20965916
40.

Effect of ceftobiprole on the normal human intestinal microflora.

Bäckström T, Panagiotidis G, Beck O, Asker-Hagelberg C, Rashid MU, Weintraub A, Nord CE.

Int J Antimicrob Agents. 2010 Dec;36(6):537-41. doi: 10.1016/j.ijantimicag.2010.07.021.

PMID:
20926263
41.

Antimicrobial susceptibility and heteroresistance in Chinese Clostridium difficile strains.

Huang H, Weintraub A, Fang H, Wu S, Zhang Y, Nord CE.

Anaerobe. 2010 Dec;16(6):633-5. doi: 10.1016/j.anaerobe.2010.09.002. Epub 2010 Sep 16.

PMID:
20849968
42.

Screening for vancomycin-resistant enterococci: results of a survey in Stockholm.

Fang H, Nord CE, Ullberg M.

APMIS. 2010 May;118(5):413-7. doi: 10.1111/j.1600-0463.2010.02605.x.

PMID:
20477819
43.

Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe: 20 years of experience.

Nagy E, Urbán E, Nord CE; ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria.

Clin Microbiol Infect. 2011 Mar;17(3):371-9. doi: 10.1111/j.1469-0691.2010.03256.x.

44.

Bacteroides fragilis RecA protein overexpression causes resistance to metronidazole.

Steffens LS, Nicholson S, Paul LV, Nord CE, Patrick S, Abratt VR.

Res Microbiol. 2010 Jun;161(5):346-54. doi: 10.1016/j.resmic.2010.04.003. Epub 2010 May 12. Erratum in: Res Microbiol. 2015 Jun;166(5):e1. Res Microbiol. 2015 Jun;166(5):e1.

45.

Effect of ceftaroline on normal human intestinal microflora.

Panagiotidis G, Bäckström T, Asker-Hagelberg C, Jandourek A, Weintraub A, Nord CE.

Antimicrob Agents Chemother. 2010 May;54(5):1811-4. doi: 10.1128/AAC.01716-09. Epub 2010 Mar 15.

46.

Antibiotic resistance patterns in gram-negative and gram-positive bacteria causing septicemia in newborns in León, Nicaragua: correlation with environmental samples.

Amaya E, Caceres M, Fanc H, Torres Ramirez A, Palmgren AC, Nord CE, Weintraub A.

J Chemother. 2010 Feb;22(1):25-9.

PMID:
20227989
47.

Metronidazole is still the drug of choice for treatment of anaerobic infections.

Löfmark S, Edlund C, Nord CE.

Clin Infect Dis. 2010 Jan 1;50 Suppl 1:S16-23. doi: 10.1086/647939. Review.

PMID:
20067388
48.

Antimicrobial resistance in Clostridium difficile.

Huang H, Weintraub A, Fang H, Nord CE.

Int J Antimicrob Agents. 2009 Dec;34(6):516-22. doi: 10.1016/j.ijantimicag.2009.09.012. Epub 2009 Oct 13. Review.

PMID:
19828299
49.

Comparison of a commercial multiplex real-time PCR to the cell cytotoxicity neutralization assay for diagnosis of clostridium difficile infections.

Huang H, Weintraub A, Fang H, Nord CE.

J Clin Microbiol. 2009 Nov;47(11):3729-31. doi: 10.1128/JCM.01280-09. Epub 2009 Sep 9.

50.

Distinct ribotypes and rates of antimicrobial drug resistance in Clostridium difficile from Shanghai and Stockholm.

Huang H, Fang H, Weintraub A, Nord CE.

Clin Microbiol Infect. 2009 Dec;15(12):1170-3. doi: 10.1111/j.1469-0691.2009.02992.x. Epub 2009 Jul 15.

Supplemental Content

Support Center